Communities›Non-Small Cell Lung Cancer Clinical Trials›Is divarasib right for my KRAS G12C lung cancer?

Is divarasib right for my KRAS G12C lung cancer?

Community Member

12 days ago

I read an article about divarasib, an investigational drug that targets KRAS G12C mutations in previously treated advanced non-small cell lung cancer. My profile lists KRAS G12C as positive, and I've had chemotherapy and immunotherapy, so this news caught my attention. My molecular testing results are marked unknown, so I'm still trying to understand where I stand. I'd love to hear from others with a similar diagnosis. - How did you learn about your KRAS status, and what was that experience like? - If you've followed research or trials for KRAS G12C, what has that been like for you? Link: https://www.statnews.com/2026/10/26/roche-kras-drug-divarasib-lung-cancer-treatment-win/

STAT

Roche gets a lung cancer win with its KRAS drug divarasib

One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which treats lung cancer.

1 comment

Comment

Community Member

12 days ago

Questions about KRAS G12C and new research like divarasib are common in non-small cell lung cancer clinical trials, and wanting clear answers makes sense. Whether an investigational drug is a fit depends on details like confirmed biomarker test results and trial eligibility, so a treatment team or a trial coordinator is the best source for that. Bringing the exact biomarker report to an appointment can help clarify where things stand, and other members are welcome to share how they learned about their KRAS status and how they follow lung cancer research.

New to the community?

Create an account to connect with others navigating cancer.

Is divarasib right for my KRAS G12C lung cancer?

Related Questions